Earnings ·
Delcath Systems reported second quarter 2026 financial results with total revenue of $29.1 million, up from $24.2…
DCTHDelcath Systems, Inc.
Delcath Systems reported second quarter 2026 financial results with total revenue of $29.1 million, up from $24.2 million in the prior year period. HEPZATO KIT revenue reached $27.1 million and CHEMOSAT revenue was $2.0 million. The company achieved a gross margin of 90% and reported net income of $2.7 million. Non-GAAP adjusted EBITDA decreased to $7.6 million from $9.8 million in the prior year quarter. Delcath increased its full-year 2026 revenue guidance to a range of $104 million to $108 million, reflecting at least 28% growth in HEPZATO KIT volume. The company ended the quarter with $95.9 million in cash and investments and no debt. Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.